SpineThera Featured at BIO - NIH SBIR Innovation Zone

SpineThera, a privately held, pre-clinical stage pharmaceutical company, has been selected to participate in the National Institutes of Health SBIR Innovation Zone at the BIO International convention to be held in San Francisco, June 6-9, 2016.

About BIO: As the world's largest biotechnology conference and exhibition, this annual event attracts 15,000 biotech leaders from 65 countries and covers the wide spectrum of life science innovations and application areas including drug discovery, bio manufacturing, genomics, biofuels, nanotechnology, cell therapy, and more.

About the BIO Innovation Zone: The NIH and NSF have continued their partnership with BIO, where nearly 100 of the most promising SBIR/STTR grantees will showcase and discuss their technologies in the exciting Innovation Zone, a premier partnering opportunity, at the BIO International Convention on June 6-9, 2016, in San Francisco, CA.

Mr. Jeff Missling, CEO of SpineThera said, "We are grateful for the support of NIH who previously funded our Phase 1 SBIR grant and now is providing this opportunity to be featured at BIO 2016. Emily Meyering, our Director of R&D, and I are looking forward to telling SpineThera's story at BIO and welcome invitations for 1:1 meetings with interested parties."

Foster and Wood Join Board of Directors

SpineThera, a privately held, pre-clinical stage pharmaceutical company, announced that John Foster and David Wood have joined its Board of Directors.

Mr. Foster previously led CNS Therapeutics through development of a 505(b)2 pain drug for site-specific administration to the central nervous system to treat intractable chronic pain. CNS was acquired by Mallinckrodt. He is currently the CEO and Chairman of NTF Therapeutics and Vice Chairman of Gillette Children's Specialty Healthcare. Jeff Missling, Chairman and CEO of SpineThera, said, "John's success in commercializing injectable drugs is directly relevant to SpineThera. He brings strong knowledge of clinical, commercial, and regulatory processes to our Board." 

Mr. Wood previously led Spinal Modulation through commercialization of a novel, implantable neuro-stimulator designed to treat intractable neuropathic pain. Spinal Modulation was acquired by St. Jude Medical. John was previously the COO of CardioNet and VP and General Manager of the Drug Delivery Business Unit at SurModics. Mr. Missling said, "Dave has excellent relationships with leading Interventional Pain physicians in the United States and abroad. He is above all a strategist with a keen focus on speed and execution." 

Foster and Wood join Mr. Jerry Jerome and Mr. Wayne Kelly on SpineThera's Board. Missling commented, "I am delighted and grateful to have John and Dave join SpineThera's Board. They both have a track record of raising significant capital from venture firms and strategic partners, and of leading a start-up through the acquisition process. In addition, they bring relevant experience from pain medicine product development. They undoubtedly strengthen SpineThera's board and position us for longer term success."

Biotech Showcase: SX600 Presentation

SpineThera, a privately held, pre-clinical stage pharmaceutical company, announced that Jeff Missling, CEO, will give a company presentation at the BioTech Showcase in San Francisco, CA on Tuesday, 12 Jan 2016 at 4:15 pm. Missling said, "Meeting participants can expect to learn more about our patented micro-suspension, sustained-release corticosteroid technology at this presentation. Our lead product candidate, SX600, is a 505(b)2 drug in development for epidural administration. Physicians routinely administer epidural injections of relatively short-acting generic steroids to treat lumbosacral radiculopathy and other back pain conditions. We aim to develop improved drugs for this underserved market."

Presentation Details:

Parc 55 Hotel, 55 Cyril Magnin Street, San Francisco, California, USA, 94102

12 Jan 2016, 4:15 pm; Track E-Davidson (4ths Floor)

Attend BioTech 2016

Closing of Series B-2 Stock Offering

SpineThera, a privately held, pre-clinical stage pharmaceutical company, announced the closing of a $2.81M preferred stock offering. SpineThera Founder and CEO, Jeff Missling, said, "With support from both existing and new investors, I am pleased to announce the closing of our Series B-2 stock offering. Raising this additional capital will enable us to aggressively pursue further development of our patented micro-suspension, sustained-release corticosteroid for epidural administration to treat back pain."

Lieutenant Governor Hosts Angel Investor Tax Credit Roundtable at SpineThera, Inc.

Founder and CEO Jeff Missling, along with 5 other Minnesota life science start-ups, participated. During the roundtable, Missling shared his experience with the Lt. Governor, stating "50% of the capital SpineThera has raised came from outside the state of Minnesota, including 5 states and 2 countries. All of our investors have participated in the Angel Tax Credit program, and it resulted in a net import of capital to Minnesota."

Read the full article here.

SpineThera Awarded $224,577 SBIR Phase I Grant from NIH

SpineThera, a privately held, pre-clinical stage pharmaceutical company, announced the award of a Phase 1 Small Business Innovation Research (SBIR) grant from the National Institute of Health.

"We are pleased to secure this non-dilutive funding from NIH that will help advance the development of our lead drug product candidate, a sustained-release injectable corticosteroid formulation that is being designed to meet the unique needs of epidural administration," said Jeff Missling, SpineThera's founder and CEO. "Our patent protected technology has the potential to significantly extend the duration of back pain relief from a single epidural injection compared to the generic steroids which are routinely used off-label today."

SpineThera was awarded $224,577 from the National Institute of Arthritis And Musculoskeletal And Skin Diseases (NIAMS) of the National Institutes of Health (NIH).

5th Annual Minnesota Entrepreneur Kick-Off

SpineThera, a privately held, pre-clinical stage pharmaceutical company, hosted a sponsor table at the 5th Annual Minnesota Entrepreneur Kick-Off.

"This was a great gathering of high-tech, life science, and clean energy companies that provided an opportunity for local entrepreneurs to learn and share their stories. I am grateful for MN-Tie and the other host organizations for pulling our community together," said Missling, SpineThera founder and CEO.

SpineThera Patent Issued

SpineThera, a privately held, pre-clinical stage pharmaceutical company, announced today that the United States Patent and Trade Mark Office has issued US Patent 8,927,529 covering sustained-release, injectable drug formulations for the treatment of back pain.

"Our novel, sustained-release technology is designed for the specific and unique requirements of injectable drugs intended for administration in and near the spine," said Jeff Missling, SpineThera's founder and CEO. "Receiving this patent is an important step in the development of our company and its technology."